ARE YOU THE โ€œ1โ€?
1 in 279 people has Lynch Syndrome. Approximately 95% of those are not aware they have Lynch Syndrome.
Surprisingly Common,
Mostly Unknown

 
 

Our Mission is to save lives by improving public and medical community awareness of Lynch Syndrome and to raise funds for Lynch Syndrome research.

Our Vision is to make a meaningful impact as a Lynch Syndrome research funding source through ongoing individual and corporate donations.

We provide support, education and resources to Lynch Syndrome carriers and their families.

 
 

WHAT IS LYNCH SYNDROME?

 Lynch Syndrome is hereditary and significantly increases the risk of colorectal, endometrial (uterine), and many other cancers.

 
 
 

 Take Action!

There are many ways you can get involved with the Jacqueline Rush Foundation and make a difference. Check out how you can help save lives!

 

SPREAD AWARENESS

The easiest way to volunteer is a simple one: Spread awareness about Lynch Syndrome! Share our website with 3 people in your social circle who have never heard of Lynch Syndrome, it takes just  a few clicks. Someone you or they know may be the โ€œ1โ€. 

VOLUNTEER

You can directly make a difference in the Lynch Syndrome community by donating your talents and your time throughout the year which helps us grow as a foundation. Your support will help spread awareness, educate the public and medical communities, and save lives!

MAKE A DONATION

Weโ€™ve made it our mission to raise awareness of Lynch Syndrome in the public and medical community. Your generosity directly helps provide support, education and resources for Lynch Syndrome carriers and their families. Your donation helps saves lives!

THE LATEST NEWS & INFORMATION

Featured
First Trial to Prove a Diet Supplement Can Prevent Hereditary Cancer
First Trial to Prove a Diet Supplement Can Prevent Hereditary Cancer

A promising clinical trial result showing that some Lynch Syndrome associated cancer risks can be reduced by over 60%!

Read More →
Small Immunotherapy Drug Trial Sees 100% Success Rate For All Participants
Small Immunotherapy Drug Trial Sees 100% Success Rate For All Participants

A small but impressive immunotherapy drug (dostarlimab) trial of stage II or III rectal cancer patients whose tumors had dMMR (mismatch repair-deficient)/high microsatellite instability (MSI-H) at Memorial Sloan Kettering Cancer Center.

Read More →
JRF Featured in Mile High Living Segment
JRF Featured in Mile High Living Segment

Joan Rush represented the Foundation and was featured in a segment on the Mile High Living show, a local news show based in Denver, CO. Joan talked about the foundation, Jacquelineโ€™s story, and the importance of knowing you have Lynch Syndrome. She also shared how easy it is to get tested for Lynch Syndrome.

Read More →
PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer
PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer

Unprecedented: This preliminary study showed complete responses in 100% of patients with locally advanced rectal cancer with mismatch repair-deficient (dMMR) tumors - a hallmark of Lynch Syndrome.

Read More →
 

โ€œLife is a certainly a journey with twisting and turning roads that can easily throw you for a loop, but only to show you that you have the courage and strength to get back up again and find your correct path. Only you can place yourself where youโ€™d like to be. Understanding this is what kept me calm and positive.โ€

โ€” Jacqueline Rush

 CONNECT WITH US ON INSTAGRAM!